

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****10/518341****DT01 Rec'd PCT/PTC 17 DEC 2004**

IN RE APPLICATION: VAN ELS, Cecile Antoinette C. M., et al. GROUP ART UNIT: TBA

SERIAL NUMBER: TBA

EXAMINER: TBA

FILED: December 17, 2004

FOR: **MHC CLASS II HAPLOTYPE SPECIFIC IMMUNODOMINANCY OF PEPTIDES DERIVED FROM RSV FUSION (F) AND ATTACHMENT (G) PROTEINS**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The Applicant(s) wish to make of record the references listed on the attached PTO/ SB/08. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references. A copy of the foreign search report is attached.

- ☐ A check is attached in the amount required under 37 CFR § 1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending applications or issued patents which may be related to the present application. A copy of the patent(s) is attached along with PTO/ SB/08.
- ☐ A check is attached in the amount required under 37 CFR § 1.17(p).

CERTIFICATION

The undersigned certifies that

- ☐ each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this statement.


PETITION

- ☐ Applicant(s) hereby request consideration of the attached information. A check is attached in the amount of the Petition fee required under 37 CFR § 1.17(i)(1).

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account No. 50-0911. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Shmuel Livnat  
Registration No. 33,949  
MCKENNA LONG & ALDRIDGE LLP  
1900 K Street, N.W.  
Washington, D.C. 20006  
Telephone No: (202) 496-7500

Date: December 17, 2004

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	TBA 10/518341
				Filing Date	December 17, 2004
				First Named Inventor	VAN ELS, Cecile Antoinette C. M., et al.
				Art Unit	TBA
				Examiner Name	TBA
Sheet	1	of	1	Attorney Docket Number	28902.0014

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	WO 92/04375	03-19-1992	NICHOLAS		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Melissa E. LEVELY, et al., "Immunodominant T-Cell Epitope on the F Protein of Respiratory Syncytial Virus Recognized by Human Lymphocytes," Journal of Virology, Vol. 65, No. 7, July 1991, pages 3789-3796	
		Paul W. TEBBEY, et al., "Atypical Pulmonary Eosinophilia is Mediated by a Specific Amino Acid Sequence of the Attachment (G) Protein of Respiratory Syncytial Virus," Journal of Experimental Medicine, Tokyo, Vol. 188, No. 10, November 16, 1998, pages 1967-1971	
		"Measurement of MHC/Peptide Interactions by Gel Filtration," Current Protocols in Immunology, Vol. 4, 1998, 18 pages	
		"Measurement of Peptide-MHC Interactions in Solution Using the Spin Column Filtration Assay," Current Protocols in Immunology, Vol. 4, 13 pages	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--